Long-term efficacy of canakinumab in crfmf

Access through your institution Buy or subscribe In patients with colchicine-resistant familial Mediterranean fever (crFMF), open-label treatment with canakinumab (150 or 300 mg every 4 or 8

weeks, with individually adjusted dose regimens) continued to control disease activity from week 40 in the phase III CLUSTER trial. During a 72-week period (weeks 41 to 113 of the trial),

>90% of the treated patients experienced no flares or had one flare, whereas a median of 17.5 flares per year was reported for the patients before entering the trial. The median

C-reactive protein serum values remained low, and no new or unexpected adverse events were reported. This is a preview of subscription content, access via your institution ACCESS OPTIONS

Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more

Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support REFERENCES ORIGINAL ARTICLE * Ozen, S. et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever:

results from the randomised phase III CLUSTER trial. _Ann. Rheum. Dis._ https://doi.org/10.1136/annrheumdis-2020-217419 (2020) Article  PubMed  Google Scholar  Download references AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Rheumatology http://www.nature.com/nrrheum/ Jessica McHugh Authors * Jessica McHugh View author publications You can also search for

this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Jessica McHugh. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE McHugh, J.

Long-term efficacy of canakinumab in crFMF. _Nat Rev Rheumatol_ 16, 408 (2020). https://doi.org/10.1038/s41584-020-0466-5 Download citation * Published: 02 July 2020 * Issue Date: August

2020 * DOI: https://doi.org/10.1038/s41584-020-0466-5 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative